(NP (NP Synergism/NN) (PP between/IN (NP the/DT (ADJP-COOD (ADJP (NP CD3/NN antigen-/NN) (ADJP *?*/-NONE-)) and/CC (ADJP CD2/NN antigen-derived/JJ)) signals/NNS)) ./.)
(NP-COOD (NP (NP Exploration/NN) (PP at/IN (NP (NP the/DT level/NN) (PP of/IN (NP (NP induction/NN) (PP of/IN (NP DNA-binding/JJ proteins/NNS))))))) and/CC (NP (NP characterization/NN) (PP of/IN (NP (NP the/DT inhibitory/JJ activity/NN) (PP of/IN (NP cyclosporine/NN))))) ./.)
(S (NP-SBJ We/PRP) (VP have/VBP (VP demonstrated/VBN (ADVP-TMP earlier/RBR) (SBAR that/IN (S (NP-SBJ (NP the/DT crosslinkage/NN) (PP of/IN (NP the/DT CD3\/TCR/NN complex/NN)) (PP with/IN (NP the/DT CD2/NN antigen/NN))) (VP results/VBZ (PP in/IN (NP (NP the/DT proliferation/NN) (PP of/IN (NP normal/JJ human/JJ T/NN cells/NNS))))))))) ./.)
(S (NP-SBJ (NP The/DT effect/NN) (PP of/IN (NP this/DT synergism/NN))) (VP was/VBD (ADJP-PRD perceptible/JJ) (PP at/IN (NP (NP the/DT level/NN) (PP of/IN (NP (NP (NP induction/NN) (PP of/IN (NP the/DT IL-2/NN gene/NN))) ,/, (NP (NP a/DT process/NN) (ADJP critical/JJ (PP for/IN (NP T/NN cell/NN growth/NN))))))))) ./.)
(S (S (NP-SBJ *-21/-NONE-) (VP To/TO (ADVP further/RB) (VP understand/VB (NP (NP the/DT (ADJP-COOD (ADJP molecular/JJ) and/CC (ADJP nuclear/JJ)) basis/NN) (PP for/IN (NP this/DT synergism/NN)))))) ,/, (NP-SBJ-21 we/PRP) (VP have/VBP (VP explored/VBN (NP (NP the/DT induction/NN) (PP of/IN (NP DNA-binding/JJ proteins/NNS)) (PP in/IN (NP (NP (ADJP highly/RB purified/VBN) normal/JJ human/JJ T/NN cells/NNS) (VP signaled/VBN (NP */-NONE-) (PP via/IN (NP the/DT (NP-COOD (NP CD3/NN) and\/or/CC (NP CD2/NN)) proteins/NNS)))))))) ./.)
(S (NP-SBJ-23 (NP The/DT effect/NN) (PP of/IN (NP (NP transmembrane/NN signaling/NN) (PP of/IN (NP T/NN cells/NNS)) (PP with/IN (NP-COOD (NP ionomycin/NN) ,/, and\/or/CC (NP sn-1,2/NN dioctanoyl/NN glycerol/NN) ,/,))))) (VP was/VBD (ADVP also/RB) (VP determined/VBN (NP *-23/-NONE-))) ./.)
(S (NP-SBJ-24 (NP The/DT emergence/NN) (PP of/IN (NP nuclear/JJ binding/NN proteins/NNS))) (VP was/VBD (VP investigated/VBN (NP *-24/-NONE-) (S (NP-SBJ */-NONE-) (VP using/VBG (NP (ADJP interleukin-2/NN sequence/NN specific/JJ) oligonucleotide/NN probes/NNS) (PP in/IN (NP the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN)))))) ./.)
(S (NP-SBJ Our/PRP$ studies/NNS) (VP demonstrate/VBP (PP-TMP for/IN (NP the/DT first/JJ time/NN)) (SBAR that/IN (S (NP-SBJ-COOD-25 (NP (ADJP CD3/NN antigen-derived/JJ) signals/NNS) and/CC (NP (ADJP CD2/NN antigen-derived/JJ) signals/NNS)) (VP are/VBP (ADJP-PRD synergistic/JJ) (PP in/IN (S (NP-SBJ *-25/-NONE-) (VP inducing/VBG (NP (NP the/DT emergence/NN) (PP of/IN (NP (NP transcription/NN factors/NNS) (SBAR (WHNP-26 that/WDT) (S (NP-SBJ *T*-26/-NONE-) (VP bind/VBP (PP to/TO (NP (NP the/DT (NP-COOD (NP NF-AT1/NN) ,/, (NP AP-1/NN) ,/, and/CC (NP NF-kB/NN)) sites/NNS) (ADJP located/JJ (PP in/IN (NP (NP the/DT promoter\/enhancer/NN region/NN) (PP of/IN (NP the/DT IL-2/NN gene/NN)))))))))))))))))))) ./.)
(S (ADVP Moreover/RB) ,/, (NP-SBJ-27 (NP cyclosporine/NN) ,/, (PP at/IN (NP (NP concentrations/NNS) (VP (ADVP readily/RB) accomplished/VBN (NP */-NONE-) (PP in/IN (NP clinical/JJ practice/NN))))) ,/,) (VP was/VBD (VP found/VBN (S (NP-SBJ *-27/-NONE-) (VP to/TO (VP inhibit/VB (NP (NP the/DT emergence/NN) (PP of/IN (NP these/DT DNA-binding/JJ proteins/NNS)) (PP-COOD (PP in/IN (NP (NP normal/JJ human/JJ T/NN cells/NNS) (VP signaled/VBN (NP */-NONE-) (PP via/IN (NP (NP cell/NN surface/NN proteins/NNS) (VP implicated/VBN (NP */-NONE-) (PP in/IN (NP antigen-dependent/JJ T/NN cell/NN activation/NN)))))))) and/CC (PP in/IN (NP (NP T/NN cells/NNS) (VP stimulated/VBN (NP */-NONE-) (PP by/IN (NP-LGS-COOD (NP (NP mobilization/NN) (PP of/IN (NP cellular/JJ calcium/NN))) and/CC (NP (NP activation/NN) (PP of/IN (NP protein/NN kinase/NN C/NN))))))))))))))) ./.)
